[Expression and Clinical Significance of miR-383-5p in Multiple Myeloma Cells]

To investigate the expression of miR-383-5p in newly diagnosed multiple myeloma (MM) and its correlation with clinical features and prognosis.

115 MM patients diagnosed and treated in the Department of Hematology, the First Affiliated Hospital of Bengbu Medical University from January 2013 to January 2017 and 115 non-tumor controls were enrolled in this study. Clinical characteristics, pathological data and therapeutic responses of the patients were collected. The expression of miR-383-5p in MM patients and non-tumor controls was detected by RT-qPCR, and the relationship between the expression level of miR-383-5p and the clinical characteristics and prognosis of MM patients was further analyzed.

The results of RT-qPCR showed that the relative expression levels of miR-383-5p in bone marrow tissues of 115 non-tumor controls and 115 MM patients were 1.89±0.11 and 1.48±0.13, respectively, and the difference was statistically significant (P < 0.05). Chi-square analysis showed that the expression of miR-383-5p was correlated with bone injury, β₂-microglobulin and globulin (all P < 0.001), but not with other factors including age, sex, hemoglobin and light chain. Univariate and multivariate Cox regression analysis indicated that low expression of miR-383-5p was an independent risk factor for poor OS in MM patients (P < 0.001).

The expression of miR-383-5p is down-regulated in MM patients, and low expression of miR-383-5p is a risk factor for poor prognosis and can be used as a new prognostic biomarker.